NASDAQ:RXDX Prometheus Biosciences (RXDX) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free RXDX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$199.60▼$199.9850-Day Range$192.50▼$199.9252-Week Range$23.27▼$199.98Volume1.86 million shsAverage Volume913,102 shsMarket Capitalization$9.56 billionP/E RatioN/ADividend YieldN/APrice Target$200.00 Stock AnalysisStock Analysis Get Prometheus Biosciences alerts: Email Address Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Prometheus Biosciences Stock (NASDAQ:RXDX)Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.Read More Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. RXDX Stock News HeadlinesMarch 6, 2024 | benzinga.comCormorant Private Healthcare Fund III LP's Net WorthMay 30, 2023 | seekingalpha.comPrometheus Biosciences: 8.5% IRR And Closing In A MonthMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.May 28, 2023 | fool.comPrometheus Biosciences (NASDAQ: RXDX)May 23, 2023 | msn.comPrometheus Biosciences gains after HSR waiting for sale to Merck expiresMay 23, 2023 | barrons.comSHAREHOLDER ALERT: Weiss Law Investigates Prometheus Biosciences, Inc.May 18, 2023 | finance.yahoo.comWhat Makes Prometheus Biosciences (RXDX) an Attractive Investment Choice?May 12, 2023 | finance.yahoo.comPrometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?March 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.May 11, 2023 | msn.comJefferies Downgrades Prometheus Biosciences (RXDX)May 11, 2023 | msn.comRBC Capital Maintains Prometheus Biosciences (RXDX) Sector Perform RecommendationMay 9, 2023 | yahoo.comPrometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate ProgressMay 1, 2023 | msn.comAbbvie, Bristol Myers competed with Merck in sale of Prometheus - reportApril 29, 2023 | finance.yahoo.comWith 67% ownership, Prometheus Biosciences, Inc. (NASDAQ:RXDX) boasts of strong institutional backingApril 21, 2023 | finance.yahoo.comPharma Stock Roundup: JNJ Beats on Q1 Earnings, MRK to Buy RXDX & Other UpdatesApril 20, 2023 | finance.yahoo.comWhy Prometheus Biosciences Stock Is Skyrocketing This WeekApril 18, 2023 | markets.businessinsider.comRBC Capital downgrades Prometheus Biosciences (RXDX) to a HoldApril 18, 2023 | finance.yahoo.comPrometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?April 18, 2023 | finance.yahoo.comHow to Tell Biotech’s Likely Winners From LosersApril 17, 2023 | benzinga.comLooking At Prometheus Biosciences's Recent Unusual Options ActivityApril 17, 2023 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Prometheus Biosciences, Inc. (RXDX)April 17, 2023 | finance.yahoo.comPrometheus (RXDX) Stock Surges 70% on Buyout Offer From MerckApril 17, 2023 | barrons.comMerck’s Deal for Prometheus Expected to Generate Billions in Additional SalesApril 17, 2023 | msn.comMerck Acquires Prometheus Biosciences for $10.8 BillionApril 17, 2023 | finance.yahoo.comMerck/Prometheus: Big Pharma must swallow bigger premiumsApril 17, 2023 | finance.yahoo.comHealthcare Is Back. But Is It Here to Stay?April 17, 2023 | investorplace.comRXDX Stock Alert: The $10.8 Billion Reason Prometheus Biosciences Is Surging TodaySee More Headlines Receive RXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:RXDX CUSIPN/A CIK1557421 Webignyta.com Phone858-422-4300FaxN/AEmployees97Year Founded1995Price Target and Rating Average Stock Price Target$200.00 High Stock Price Target$200.00 Low Stock Price Target$200.00 Potential Upside/Downside+0.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,750,000.00 Net Margins-3,768.76% Pretax Margin-3,768.76% Return on Equity-33.50% Return on Assets-29.59% Debt Debt-to-Equity Ratio0.04 Current Ratio37.56 Quick Ratio37.56 Sales & Book Value Annual Sales$6.81 million Price / Sales1,403.55 Cash FlowN/A Price / Cash FlowN/A Book Value$16.12 per share Price / Book12.40Miscellaneous Outstanding Shares47,810,000Free Float46,187,000Market Cap$9.56 billion OptionableNot Optionable Beta-0.49 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Mark C. McKenna (Age 43)Pres, CEO & Chairman Comp: $1.33MDr. Keith W. Marshall M.B.A. (Age 55)MBA, Ph.D., Chief Financial Officer Comp: $829.45kMr. Mark Stenhouse (Age 56)Chief Operating Officer Comp: $807.4kDr. Olivier Laurent Ph.D. (Age 51)Chief Scientific Officer & Head of R&D Ms. Noel KurdiVP of Investor Relations & CommunicationsMr. Timothy K. Andrews Esq. (Age 44)Gen. Counsel & Sec. Ms. Nori Ebersole (Age 59)Chief People Officer Dr. Allison Luo M.D. (Age 50)Chief Medical Officer Dr. Thierry Dervieux DABCC (Age 55)Ph.d., Pharm.d., Chief Devel. Officer of Diagnostics & Medical Laboratory Director Mr. Chris DoughtyChief Bus. OfficerMore ExecutivesKey CompetitorsImmunoGenNASDAQ:IMGNRayzeBioNASDAQ:RYZBBio-Rad LaboratoriesNYSE:BIO.BChemedNYSE:CHEBio-Rad LaboratoriesNYSE:BIOView All CompetitorsInsidersKeith W MarshallSold 10,000 sharesTotal: $1.08 M ($108.42/share) RXDX Stock Analysis - Frequently Asked Questions Should I buy or sell Prometheus Biosciences stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXDX, but not buy additional shares or sell existing shares. View RXDX analyst ratings or view top-rated stocks. What is Prometheus Biosciences' stock price target for 2024? 7 Wall Street research analysts have issued 12-month price objectives for Prometheus Biosciences' stock. Their RXDX share price targets range from $200.00 to $200.00. On average, they predict the company's share price to reach $200.00 in the next twelve months. This suggests a possible upside of 0.0% from the stock's current price. View analysts price targets for RXDX or view top-rated stocks among Wall Street analysts. How were Prometheus Biosciences' earnings last quarter? Prometheus Biosciences, Inc. (NASDAQ:RXDX) released its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $0.06. The biopharmaceutical company earned $1.11 million during the quarter, compared to the consensus estimate of $0.46 million. Prometheus Biosciences had a negative net margin of 3,768.76% and a negative trailing twelve-month return on equity of 33.50%. The business's revenue was down 71.8% compared to the same quarter last year. What ETF holds Prometheus Biosciences' stock? Vanguard Russell 2000 Growth ETF holds 27,868 shares of RXDX stock, representing 0.58% of its portfolio. What other stocks do shareholders of Prometheus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD). When did Prometheus Biosciences IPO? Prometheus Biosciences (RXDX) raised $126 million in an IPO on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities served as the underwriters for the IPO. Does Prometheus Biosciences have any subsidiaries? The following companies are subsidiares of Prometheus Biosciences: Prometheus Laboratories Inc..Read More This page (NASDAQ:RXDX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prometheus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.